Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status

Critical Reviews in Oncology/Hematology

Volumn 78, Issue 3, 2011, Pages 243-251

  Fornaro, Lorenzo ^a   Baldi, Giacomo Giulio ^a   Masi, Gianluca ^a   Allegrini, Giacomo ^b   Loupakis, Fotios ^a   Vasile, Enrico ^a   Cupini, Samanta ^c   Stasi, Irene ^a   Salvatore, Lisa ^a   Cremolini, Chiara ^a   Vincenzi, Bruno ^d   Santini, Daniele ^d   Tonini, Giuseppe ^d   Graziano, Francesco ^e   Ruzzo, Annamaria ^f   Canestrari, Emanuele ^f   Magnani, Mauro ^f   Falcone, Alfredo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b Ospedale F Lotti   (Italy)

^c UO Oncologia Medica   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e SAN SALVATORE HOSPITAL   (Italy)

^f UNIVERSITY OF URBINO   (Italy)

Author keywords

BRAF; Cetuximab; Chemotherapy; Elderly; KRAS; Metastatic colorectal cancer

Indexed keywords

B RAF KINASE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN;

AGED; ANEMIA; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 79955672069     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.06.003     Document Type: Review

References (29)

1. Merlin F., Prochilo T., Tondulli L., et al. Colorectal cancer treatment in elderly patients: an update on recent clinical studies. Clin Colorectal Cancer 2008, 7:357-363.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
3. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
4. McKibbin T., Frei C.R., Greene R.E., et al. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 2008, 13:876-885.
5. Raftery L., Sanoff H.K., Goldberg R. Colon cancer in older adults. Semin Oncol 2008, 35:561-568.
6. Papamichael D., Audisio R., Horiot J.C., et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009, 20:5-16.
7. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to ECOG performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002, 20:494-502.
8. Chau I., Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br J Cancer 2009, 100:1704-1719.
9. Köhne C.H., Lenz H.J. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009, 14:478-488.
10. Kabbinavar F.F., Hurwitz H.I., Yi J., et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2008, 27:199-205.
11. Kozloff M.F., Sugrue M.M., Purdie D.M., et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. J Clin Oncol 2008, 26(May 20 Suppl.). abs 4026.
12. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study. Eur J Cancer Suppl 2009, 7(2). abs 6088.
13. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory colorectal cancer. N Engl J Med 2004, 351:337-345.
14. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
15. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
16. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
17. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
18. Bouchahada M., Macarulla T., Spano J.P., et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 2008, 67:255-262.
19. Sastre J., Aranda E., Grávalos C., et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 2009, (December). [Epub ahead of print]. doi:10.1016/j.critrevonc.2009.11.005.
20. Rivera F., Gravalos C., Massuti B., et al. Cetuximab and capecitabine as first line treatment for elderly patients with metastatic colorectal cancer: preliminary results of TTD trial. Eur J Cancer Suppl 2009, 7(2). abs 4004.
21. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
22. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
23. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
24. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
25. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
26. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. EORTC, NCI USA, NCI Canada. J Natl Cancer Inst 2000, 92:205-216.
27. Loupakis F., Pollina L., Stasi I., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:2622-2629.
28. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. 2010 Gastrointestinal Cancers Symposium, abs 281.
29. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study. 2010 Gastrointestinal Cancers Symposium, abs 428.